News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Upstream Biosciences Inc. Expects Increased Interest From Big Pharma as FDA's Proposed Priority Review Voucher Program Is Implemented


6/10/2008 10:24:09 AM

VANCOUVER, BC--(Marketwire - June 10, 2008) - Upstream Biosciences Inc. (OTCBB: UPBS) announced today that the United States Food and Drug Administration's (FDA) proposed priority review voucher program to stimulate development of drugs for tropical diseases could increase and accelerate the financial returns for small companies with the most promising technologies.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES